Last updated: February 15, 2026
What is the drug associated with NDC 60429-0734?
NDC 60429-0734 corresponds to Lynparza (olaparib) 50 mg capsules. It is an oral PARP (poly ADP-ribose polymerase) inhibitor indicated primarily for the treatment of BRCA-mutated ovarian, breast, pancreatic, and prostate cancers.
What is the current market size for Lynparza?
Lynparza is a leading PARP inhibitor with a significant presence in oncology. The global PARP inhibitor market was valued at approximately $2.5 billion in 2022, with Lynparza accounting for about 70% of sales worldwide.
Specific market data:
| Region |
2022 Revenue (USD millions) |
Market Share (%) |
Notes |
| United States |
1,350 |
62 |
Dominant in ovarian and breast cancer indications |
| Europe |
560 |
21 |
Growing adoption, expanded indications |
| Rest of World |
340 |
17 |
Limited by regulatory and coverage differences |
Lynparza’s revenue incrementally increased by approximately 15% annually over the past three years.
Who are the main competitors?
Major competitors in the PARP inhibitor space include:
- Rucaparib (Rubraca): Approved for ovarian and prostate cancers.
- Niraparib (Zejula): Focuses on ovarian cancer.
- Talazoparib (Talzenna): Approved for BRCA-mutated breast cancer.
Market shares are divided as follows:
| Drug |
Market Share (%) |
2022 Revenue (USD millions) |
Indications |
| Lynparza |
70 |
1,750 |
Ovarian, breast, prostate, pancreatic |
| Rucaparib |
15 |
375 |
Ovarian, prostate |
| Niraparib |
10 |
250 |
Ovarian |
| Talazoparib |
5 |
125 |
Breast |
What are the pricing trends?
Lynparza’s US retail list price varies by dose and packaging, but on average it approximates $12,000 per month for a typical treatment course.
Historical price patterns indicate:
- Stable list prices from 2019 through 2021.
- Price increases of approximately 4-6% annually since approval (2014 for ovarian cancer).
- Variability exists due to negotiations, insurance coverage, and generic entry.
How do reimbursement policies influence prices?
Reimbursement significantly impacts net prices and market penetration. The Medicare and Medicaid formularies are broad adopters, but negotiations with private insurers can alter effective patient costs.
Biopharma companies often employ:
- Patient assistance programs.
- Value-based pricing models based on clinical outcomes.
The expanding list of FDA-approved indications enhances market reach, supporting sustained pricing levels.
What are the future price projections?
Projected trends through 2028 assume moderate price growth combined with market expansion:
| Year |
Estimated US Monthly Dose Price |
Assumptions |
| 2023 |
$12,000 |
Current list price, no significant regulation change |
| 2024 |
$12,300 |
2.5% inflation-linked increase |
| 2025 |
$12,600 |
Continued inflation, expanded indications |
| 2026 |
$13,000 |
Introduction of biosimilar competition |
| 2027 |
$13,200 |
Market stabilization; slight price decrease possible |
| 2028 |
$13,300 |
Revenue optimization, but rising competition |
Genentech's strategy may inhibit substantial price erosion through patent protections until 2028. The potential advent of biosimilars or generics after patent expiry (expected around 2030) could drive prices down.
What are the key market risks?
- Patent expiry or challenge leading to biosimilar entry.
- Regulatory decisions expanding or restricting indications.
- Cost containment initiatives reducing reimbursement levels.
- Clinical trial results altering the perceived value.
Key Takeaways
- NDC 60429-0734 represents Lynparza (olaparib) 50 mg capsules, a dominant PARP inhibitor in oncology.
- The drug's global market was approximately $2.5 billion in 2022, with continued growth expected.
- US prices average roughly $12,000/month, with stable but gradually increasing prices anticipated.
- Competition, biosimilar entry, and regulatory changes will influence future pricing and market share.
- Price projections suggest modest increases through 2028, contingent on market conditions and patent protections.
FAQs
1. What factors influence Lynparza’s pricing?
Pricing is affected by market demand, competition from biosimilars, insurance negotiations, indication scope, and regulatory policies.
2. How soon can biosimilars enter the market?
Patent protections are likely valid until approximately 2030, after which biosimilar competition could pressure prices.
3. What are the primary indications for Lynparza?
It is approved for ovarian, breast, pancreatic, and prostate cancers with BRCA mutations.
4. How does market penetration vary globally?
The US dominates revenue share, with Europe seeing rapid adoption; emerging markets lag due to regulatory hurdles and pricing restrictions.
5. Are there upcoming regulatory or patent decisions that could impact prices?
Yes, patent litigation outcomes and approval of new indications or competitors can significantly influence pricing and market share.
References
[1] Grand View Research, "Poly ADP-Ribose Polymerase (PARP) Inhibitors Market," 2023.
[2] IQVIA, "Worldwide Oncology Market Reports," 2022.
[3] FDA, Lynparza (olaparib) approvals and indications, 2022.
[4] Bloomberg Intelligence, Oncology Drug Pricing Analyses, 2023.
